R117H Mutations: Genotype-Phenotype and its Presence in the NBS Panel. I. Bronsveld 1 , R.A. de Nooijer 1 , H.G.M. Arets 2 , F. Teding van Berkhout 1 , Y. de Rijke 3 , H.R. de Jonge 4. 1 Dept. of Pulmonology and 2 Dept. of Paediatrics, UMC Utrecht, The Netherlands; 3 Dept. of Clinical
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
R117H Mutations: Genotype-Phenotype and its Presence in the NBS Panel
I. Bronsveld1, R.A. de Nooijer1, H.G.M. Arets2, F. Teding van Berkhout1, Y. de Rijke3, H.R. de Jonge4.
1Dept. of Pulmonology and 2Dept. of Paediatrics, UMC Utrecht, The Netherlands; 3Dept. of Clinical
Chemistry and 4Dept. of Biochemistry, Erasmus MC Rotterdam, The Netherlands.
In spite of the evolving possibilities in CF diagnostic methods and CFTR function tests, in a group of CFTR mutations genotype – phenotype relationships continue to be difficult. Recently, various studies have suggested to categorize the different mutations into groups depending on their possible clinical outcome (Castellani 2008, Farrell 2008). However, mutations such as R117H do not fit in the classification in this manner because of the wide variation in phenotype. In addition, R117H can be found in cis with T5 or T7 which further influence phenotype.
To gain further insight into CFTR function and clinical presentation of the R117H mutation. This is especially relevant for a large proportion of persons who tested positive in our newborn screening test by IRT: Until now during neonatal screening using IRT, PAP and DNA analysis we found R117H in 7 out of 18 CF patients (40%), compared to around 1-5% in CF patients diagnosed on clinical grounds.
We compared clinical presentation of our homozygous R117H patients.
Function tests were performed: nasal potential difference (NPD) and intestinal current measurement (ICM) for CFTR function in the respiratory and intestinal epithelium respectively, sweat test, and fecal elastase to address pancreatic function.
Graph 2. NPD and ICM tracing of the R117H homozygous female.
NPD: Basal -12mV; Cl-free+Iso -24mV ICM: carb 33.6µA/cm2
In our group of 230 paediatric and 150 adult CF patients there were two homozygous R117H (7T/7T) patients, one male (age 35) and one female (age 33). The male patient presented with infertility and appeared to have CBAVD. The female person was only recognised because she underwent CFTR mutation analysis after her son was identified with F508del/R117H by the newborn screening test. She had no clinical symptoms. When measuring NPD in these subjects (Graph 1&2), there was a normal basal PD, amiloride response and total chloride conductance. Cl- secretory responses in ICM upon carbachol addition were within the normal range. Sweat tests in both persons were borderline (Cl- 34 and 42 respectively) and faeces elastases were normal (> 200 μg/g faeces).
Graph 1. NPD and ICM tracing of the R117H homozygous male.
NPD: Basal -25mV; Cl-free+Iso -11mV ICM: carb 31.9µA/cm2